Randomized Phase II to Assess the Efficacy of Whole Brain Radiation Therapy (WBRT) With Concomitant Gefitinib Followed by Maintenance Gefitinib, and Gefitinib Alone, in Lung Cancer Patients With Brain Metastasis

Trial Profile

Randomized Phase II to Assess the Efficacy of Whole Brain Radiation Therapy (WBRT) With Concomitant Gefitinib Followed by Maintenance Gefitinib, and Gefitinib Alone, in Lung Cancer Patients With Brain Metastasis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2014

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Brain metastases; Lung cancer
  • Focus Therapeutic Use
  • Acronyms ARPEGE
  • Most Recent Events

    • 21 Jun 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 21 Jun 2012 Planned end date changed from 1 May 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 21 Jun 2012 Actual initiation date changed from May 2011 to Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top